| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/CNCR.11479 |
| P8608 | Fatcat ID | release_hiiwf6racnbrnentbmroyxpsru |
| P698 | PubMed publication ID | 12872348 |
| P5875 | ResearchGate publication ID | 10653021 |
| P50 | author | Russell E. Lewis | Q38327565 |
| Hagop Kantarjian | Q60394812 | ||
| Dimitrios P Kontoyiannis | Q88469665 | ||
| Richard E Champlin | Q89187648 | ||
| P2093 | author name string | Gerald P Bodey | |
| Issam I Raad | |||
| Ray Hachem | |||
| Harrys A Torres | |||
| John Thornby | |||
| Gustavo A Rivero | |||
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Aspergillosis case-fatality rate: systematic review of the literature | Q31918085 | ||
| Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study | Q33719197 | ||
| Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America | Q33894472 | ||
| Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group | Q34002098 | ||
| Rationale for combination antifungal therapy | Q34335236 | ||
| A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America | Q34335250 | ||
| Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. | Q34455633 | ||
| Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections | Q34481664 | ||
| Invasive aspergillosis in 2002: an update | Q34603584 | ||
| Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. | Q38016840 | ||
| In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. | Q39651019 | ||
| Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis | Q39652561 | ||
| Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients | Q40620077 | ||
| Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development | Q41740968 | ||
| Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis | Q43864353 | ||
| Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans | Q43933917 | ||
| Voriconazole versus amphotericin B for invasive aspergillosis | Q44255081 | ||
| Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin | Q44304226 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| aspergillosis | Q259626 | ||
| toxicity | Q274160 | ||
| invasive aspergillosis | Q3625278 | ||
| amphotericin B | Q412223 | ||
| P1104 | number of pages | 8 | |
| P304 | page(s) | 292-299 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies | |
| P478 | volume | 98 |
| Q36895839 | A comparative evaluation of properties and clinical efficacy of the echinocandins |
| Q43742898 | A rescue therapy with a combination of caspofungin and liposomal amphotericin B or voriconazole in children with haematological malignancy and refractory invasive fungal infections |
| Q36259905 | Advances and challenges in management of invasive mycoses |
| Q46788198 | Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy |
| Q54394711 | An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. |
| Q42545764 | Anidulafungin in combination with amphotericin B against Aspergillus fumigatus |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q37161793 | Antifungal therapies in the intensive care unit |
| Q37421528 | Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update |
| Q37873552 | Antifungal treatment strategies in patients with haematological diseases or cancer: from prophylaxis to empirical, pre-emptive and targeted therapy |
| Q39987609 | Aspergillosis in hematopoietic stem cell transplant recipients: risk factors, prophylaxis, and treatment |
| Q33719294 | Aspergillus infections in transplant recipients |
| Q90297410 | Candida Infections and Therapeutic Strategies: Mechanisms of Action for Traditional and Alternative Agents |
| Q42822258 | Caspofungin after solid organ transplantation in Germany: observational study on treatment of invasive fungal infections |
| Q46653990 | Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. |
| Q46401414 | Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation |
| Q37159584 | Caspofungin for treatment of invasive aspergillus infections. |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q35537846 | Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis |
| Q36278031 | Caspofungin: an overview |
| Q28539197 | Characterization of Scedosporium apiospermum glucosylceramides and their involvement in fungal development and macrophage functions |
| Q64070463 | Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B |
| Q30873926 | Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data |
| Q37000091 | Combination antifungal therapy for the treatment of invasive yeast and mold infections |
| Q45912149 | Combination antifungal therapy: from bench to bedside. |
| Q36847555 | Combination antifungal therapy: what can and should we expect? |
| Q36960092 | Combination antifungals: an update |
| Q46933663 | Combination therapy for invasive aspergillosis |
| Q38806932 | Combination therapy for the treatment of pulmonary mold infections |
| Q33857685 | Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus |
| Q46039199 | Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp. |
| Q28273738 | Comparison of echinocandin antifungals |
| Q38284463 | Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. |
| Q36357893 | Current approaches to diagnosis and treatment of invasive aspergillosis |
| Q53217028 | Current role of echinocandins in the management of invasive aspergillosis. |
| Q36484950 | Decision making in antifungal monotherapy versus combination therapy |
| Q37463228 | Diagnosis and treatment of aspergillosis in children |
| Q42954068 | Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? |
| Q41985252 | EDTA as an adjunct antifungal agent for invasive pulmonary aspergillosis in a rodent model |
| Q37822777 | Echinocandin antifungal drugs in fungal infections: a comparison |
| Q36441524 | Echinocandin antifungals: review and update |
| Q28264860 | Echinocandins in the management of invasive fungal infections, Part 2 |
| Q36222035 | Echinocandins: role in antifungal therapy, 2005. |
| Q34352222 | Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. |
| Q36341374 | Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q53175359 | Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies. |
| Q42038850 | Eradication of pulmonary aspergillosis in an adolescent patient undergoing three allogeneic stem cell transplantations for acute lymphoblastic leukemia. |
| Q33867013 | Factors associated with mortality in transplant patients with invasive aspergillosis |
| Q36278069 | Fungal CNS infections in patients with hematologic malignancy. |
| Q37739908 | Fungal infections after hematopoietic stem cell transplantation |
| Q36616182 | Fungal pneumonia due to molds in patients with hematological malignancies |
| Q38173720 | High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events |
| Q51186226 | High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. |
| Q26999448 | How to manage aspergillosis in non-neutropenic intensive care unit patients |
| Q35568846 | How to treat fungal infections in ICU patients |
| Q41815954 | In vitro activities of 35 double combinations of antifungal agents against Scedosporium apiospermum and Scedosporium prolificans |
| Q36396105 | Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro |
| Q38066616 | Invasive aspergillosis in the intensive care unit |
| Q36895540 | Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients |
| Q53567263 | Invasive fungal infections in living unrelated renal transplantation. |
| Q44686777 | Invasive fungal infections in patients with hematologic malignancies: the next steps |
| Q81434718 | Invasive mycoses in children receiving hemopoietic SCT |
| Q46946844 | Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). |
| Q36087577 | Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients |
| Q51187346 | Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. |
| Q35026516 | Micafungin in the treatment of invasive candidiasis and invasive aspergillosis |
| Q43718029 | Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study |
| Q36222041 | New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients |
| Q36597431 | New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage |
| Q35917388 | New developments in antifungal strategy |
| Q46840248 | Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin |
| Q37178176 | Optimizing efficacy of Amphotericin B through nanomodification. |
| Q35756513 | Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination |
| Q37405284 | Paradoxical echinocandin activity: a limited in vitro phenomenon? |
| Q34352014 | Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection |
| Q57746174 | Pharmacological and Host Considerations Surrounding Dose Selection and Duration of Therapy with Echinocandins |
| Q36150713 | Pharmacotherapy of onychomycosis |
| Q35666527 | Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients |
| Q36323256 | Posaconazole: a broad-spectrum triazole antifungal |
| Q34532546 | Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America |
| Q38296370 | Randomised, multicentre trial of micafungin vs. an institutional standard regimen for salvage treatment of invasive aspergillosis. |
| Q34151170 | Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. |
| Q28077381 | Recent developments in the management of invasive fungal infections in patients with oncohematological diseases |
| Q36531721 | Review of epidemiology, diagnosis, and treatment of invasive mould infections in allogeneic hematopoietic stem cell transplant recipients |
| Q35799730 | Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients |
| Q44925292 | Safety and efficacy of caspofungin and liposomal amphotericin B, followed by voriconazole in young patients affected by refractory invasive mycosis |
| Q34543970 | Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis |
| Q35587115 | Status of combination therapy for refractory mycoses |
| Q36568458 | Strategies to enhance immune function in hematopoietic transplantation recipients who have fungal infections |
| Q46758158 | Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome |
| Q81086319 | Supportive care |
| Q35828187 | Toward more effective antifungal therapy: the prospects of combination therapy. |
| Q33384785 | Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data |
| Q34357504 | Treatment options in Invasive Aspergillosis |
| Q43191432 | Update: invasive fungal infections: Diagnosis and treatment in surgical intensive care medicine |
| Q42377772 | Voriconazole plus caspofungin for treatment of invasive fungal infection in children with acute leukemia |
| Q45942581 | [Potential of anidulafungin in combined therapy]. |
| Q45942584 | [Potential of anidulafungin in hematological patients]. |
Search more.